JPMorgan lowered the firm’s price target on PTC Therapeutics to $43 from $45 and keeps an Overweight rating on the shares. The analyst cites reduced forecasts for Tegsedi and Upstaza for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTCT:
- PTC Therapeutics price target lowered to $22 from $27 at RBC Capital
- PTC Therapeutics Faces Negative EMA Opinion on Translarna Renewal
- PTC Therapeutics falls 10% to $23.88 after CHMP negative opinion for Translarna
- PTC Therapeutics: CHMP issues negative opinion for Translarna renewal
- Citi opens ‘negative catalyst watch’ on PTC Therapeutics into EU decision